Niclosamide can inhibit various molecular pathways (e.g., STAT3, mTOR) that are dysregulated in ALS, suggesting its potential to disrupt these altered mechanisms associated with the pathology. The gene discussed is STAT3; the disease is amyotrophic lateral sclerosis.